-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
October 10, 2020 /--- In June this year, two papers published in the journal Science reported on an antibody cocktail (also known as antibody mixture) against coronavirus SARS-CoV-2, developed by exploring humanized mice and rehabilitation patients (Science, 2020, doi:10.1126/science.abd827; Science, 2020, doi:10.1126/science.abd0831).
antibody cocktail, developed by the U.S. Government, consists of two antibodies, REK10987 and REK10933, binds to the coronavirus, reducing the risk of it developing resistance.
now, in a new study that builds on both papers, researchers have found that the antibody cocktail, whether preventive or therapeutic, benefits animal models that simulate different pathology of SARS-CoV-2 infection.
results were published online October 9, 2020 in the journal Science under the title "REGN-COV2 antibodies prevent and treat SARS-CoV-2 infect in rhesus macaques and hamsters".
images from Science, 2020, doi:10.1126/science.abe2402.
the potential of this approach in preventing and treating SARS-CoV-2 diseases," the researchers said.
" Although several studies have found and masted strong-acting and monoclonal antibodies against SARS-CoV-2, the evaluation of their efficacy in the body is limited and focused on preventive conditions.
addition, there is no animal model more relevant to human diseases, leading some to point out that multiple animal models may be needed to simulate human infections.
Based on two papers published in the Journal of Science in June by Johanna Hansen et al. and Alina Baum et al. identifying and presenting a double antibody therapy, Baum and colleagues tested the antibody cocktail called REGN-COV2 in rhesus monkeys showing mild COVID-19 symptoms and golden hamsters showing more severe COVID-19 symptoms, including rapid weight loss.
the researchers say the treatment almost completely stopped viral infections in rhesus monkeys when regency regency three days before the SARS-CoV-2 virus challenge.
that this capability "is equivalent to or exceeds the effects shown in recent vaccine efficacy studies using the same animal models."
rhesus monkeys treated with REGN-COV2 a day after infection with SARS-CoV-2, the researchers reported that the virus cleared faster than the untreated control group.
, the researchers used a golden hamster model to assess reGEN-COV2's ability to change the course of disease in more severe cases.
treatment with REGN-COV2 two days before infection with SARS-CoV2 prevented golden hamsters from "significantly losing weight" and reduced viral load in their lungs.
also reported the benefits of receiving REGN-COV2 treatment one day after the golden hamster was infected with SARS-CoV-2 compared to the control group.
Our findings are that our data provide evidence that REN-COV2-based treatment may provide clinical benefits in the prevention and treatment of COVID-19 diseases, and we are currently evaluating this antibody cocktail," the researchers said.
.com Related News: 1.Science: Antibody combinations targeting SARS-CoV-2 hedgehog proteins prevent escape mutations that are rapidly produced during single antibody therapy 2.Science.ScienceDaily Find powerful antibody combinations with potential to treat COVID-19 Source: 1.Alina Baum-2 et al. REGN-COV2 anti preventbodies and treat SARS-CoV-2 infect in rhesus macaques and hamsters. Science, 2020, doi:10.1126/science.abe2402.More evidence of benefits of REGN-COV2 antibody cocktail to both protect from treat and disease.